| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2015-01-12 | MedImmune (USA - global biologics arm of AstraZeneca (UK) Omnis Pharmaceuticals (USA - MN) | oncolytic virus programme | licensing |
Cancer - Oncology | Licensing agreement | |
| 2015-01-12 | Retrophin (USA - CA) Asklepion Pharmaceuticals (USA - MD) | Cholbam® (cholic acid) capsules | patients with bile acid synthesis disorders due to single enzyme defects patients with peroxisomal disorders (including Zellweger spectrum disorders) | product acquisition |
Rare diseases - Genetic diseases - Metabolic diseases | Product acquisition |
| 2015-01-11 | ArcherDX (USA - CO) Qiagen (The Netherlands) | distribution |
Technology - Services | Distribution agreement | ||
| 2015-01-11 | illumina (USA - CA) University of Edinburgh (UK) University of Edinburgh Glasgow (UK) | collaboration |
Technology - Services - Cancer - Oncology - CNS diseases | Collaboration agreement | ||
| 2015-01-09 | BiogenIdec (USA - MA) Columbia University Medical Center (USA - NY) | diseases with significant unmet clinical need such as amyotrophic lateral sclerosis and idiopathic pulmonary fibrosis | R&D |
Lung diseases - Respiratory diseases - Rare diseases - Neurodegenerative diseases | R&D agreement | |
| 2015-01-09 | Incyte (USA - DE) | nomination |
Nomination | |||
| 2015-01-09 | Isis Pharmaceuticals (USA - CA) Alnylam Pharmaceuticals (USA - MA) | RNA therapeutics including oligonucleotide therapeutics against Factor XI and apolipoprotein (a) | development licensing commercialisation |
Cardiovascular diseases - Hematological diseases - Genetic diseases - Rare diseases | Development agreement | |
| 2015-01-09 | bioMerieux (France) Copan (Italy) | automated platforms including the WASP® Walk-Away Specimen Processor and the WASPLab™ solutions | collaboration distribution |
Diagnostic | Distribution agreement | |
| 2015-01-09 | Polyphor (Switzerland) PARI Pharma (Germany) | eFlow® Technology nebulizer | licensing |
Rare diseases - Genetic diseases - Lung diseases | Licensing agreement | |
| 2015-01-09 | Mission Therapeutics (UK) | nomination |
Cancer - Oncology | Nomination | ||
| 2015-01-09 | Aveo Oncology (USA - MA) | nomination |
Cancer - Oncology | Nomination | ||
| 2015-01-08 | Helsinn (Switzerland) Pharmacosmos (Denmark) | Monofer® | iron deficiency anemia | licensing development commercialisation |
Licensing agreement | |
| 2015-01-08 | Cardio3 BioSciences (Belgium) | nomination |
Cardiovascular diseases - Regenerative Medicine | Nomination | ||
| 2015-01-08 | Proteros biostructures (Germany) Bayer Pharma (Germany) | R&D |
Cardiovascular diseases | R&D agreement | ||
| 2015-01-08 | Abcam (UK) Institute of Molecular and Cell Biology (IMCB) (Singapore) | RabMAb® antibody pairs | R&D |
Technology - Services | R&D agreement | |
| 2015-01-08 | Melinta Therapeutics (USA - CT) Eurofarma Laboratórios (Brazil) | delafloxacin | acute bacterial skin and skin structure infections (ABSSSI) | commercialisation - distribution | Infectious diseases | Commercialisation agreement |
| 2015-01-07 | Exelixis (USA) Sobi - Swedish Orphan Biovirum (Sweden) | Cometriq™(cabozantinib) | metastatic medullary thyroid cancer | commercialisation |
Cancer - Oncology - Rare diseases | Distribution agreement |
| 2015-01-07 | NIH (USA) Vtesse (USA - MD) | Niemann-Pick disease type C and other lysosomal storage disorders | R&D agreement |
Rare diseases | R&D agreement | |
| 2015-01-07 | Novartis (Switzerland) Intellia Therapeutics (USA - MA) | CRISPR/Cas9-based therapies | R&D |
R&D agreement | ||
| 2015-01-07 | BioMarin Pharmaceutical (USA - CA) | nomination |
Rare diseases | Nomination |
